EirGen Pharma Product Dossier Eir-051 submitted in Canada

EirGen Pharma are pleased to report that the dossier for product Eir-051 was submitted to Health Canada in June 2008. This product was developed as a treatment for early stage breast cancer and approval is anticipated for the end of 2009.

Technical Director Tom Brennan stated that "this is a very significant achievement for us with this product that passed clinical trial in Q1 2008, as it is also our first dossier submission in Canada". Managing Director Patsy Carney stated that "another key milestone reached for EirGen with our first Canadian submission. It is also extremely encouraging for us as we are a young company who are proving our consistent ability to deliver key Niche products on time".

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets